Physician profile
Robert Goldberg
NPI 1033123203
$4,608.76
in general payments reported to CMS, 2019-2025
14 companies · $1,354 in 2025
The $1,354 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2021: $267 · 2022: $929 · 2023: $358 · 2024: $674 · 2025: $1,354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,386.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $899.10 | 2019-2022 | |
| Abbvie INC. | $658.88 | 2024-2025 | |
| Galderma Laboratories, L.P. | $502.70 | 2019 | |
| Horizon Therapeutics Plc | $441.34 | 2019-2023 | Tepezza |
| Stryker Corporation | $440.89 | 2019-2025 | Flowtriever, Na |
| Amgen INC. | $402.49 | 2024-2025 | Tepezza |
| Biotissue Holdings INC. | $344.60 | 2021-2025 | |
| Merz North America, INC. | $256.00 | 2019-2023 | Xeomin |
| Aerin Medical INC. | $188.14 | 2025 | |
| Medtronic, INC. | $153.46 | 2025 | Stealthstation S8 Platform |
| Genentech USA, INC. | $138.05 | 2021 | |
| Argenx US, INC. | $98.96 | 2025 | |
| Merz Pharmaceuticals, LLC | $48.73 | 2022 | |
| Lifenet Health | $35.42 | 2024 | Theragenesis Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Goldberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.